<unk>  does not alter daytime vigilance and memory in healthy volunteers. In depressed patients, treatment with the drug increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency.<unk>  also induced an advance of the time of sleep onset and of minimum heart rate. From the first week of treatment, onset of sleep and the quality of sleep were significantly improved without daytime clumsiness as assessed by patients.<unk>  appears to cause fewer sexual side effects and discontinuation effects than paroxetine. ; Common (1–10% incidence) adverse effects include * Hyperhidrosis (excess sweating that is not proportionate to the ambient temperature) * Abdominal pain * Nausea * Vomiting * Diarrhea * Constipation * Back pain * Fatigue * Increased ALAT and ASAT (liver enzymes) * Headache * Dizziness * Somnolence * Insomnia * Migraine * Anxiety ; Uncommon (0.1–1%) adverse effects include * Paraesthesia (abnormal sensations e.g. itching, burning, tingling, etc. due to malfunctioning of the peripheral nerves) * Blurred vision * Eczema * Pruritus (itching) * Urticaria * Agitation * Irritability * Restlessness * Aggression * Nightmares * Abnormal dreams ; Rare (0.01–0.1%) adverse effects include * Mania * Hypomania * Suicidal ideation * Suicidal behaviour * Hallucinations * Steatohepatitis * Increased GGT and/or alkaline phosphatase * Liver failure * Jaundice * Erythematous rash * Face oedema and angioedema * Weight gain or loss, which tends to be less significant than with SSRIs Dependence and withdrawal No dosage tapering is needed on treatment discontinuation.<unk>  has no abuse potential as measured in healthy volunteer studies.
Agomelatine
Tropisetron
Granisetron
Alosetron
Avacopan
Cabergoline
Loteprednol
Cilansetron